Last reviewed · How we verify
Long Tirofiban
At a glance
| Generic name | Long Tirofiban |
|---|---|
| Also known as | Aggrastat |
| Sponsor | Medicure |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Tirofiban After Successful MT Recanalization in AIS (PHASE2, PHASE3)
- HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN) (PHASE3)
- Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention (PHASE2)
- Tirofiban in Stenting for Long Coronary Lesion (PHASE4)
- Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |